Received: 8 June 2021
Accepted: 6 August 2021
First Online: 3 September 2021
: This study was authorised by the Data Protection Officer of our hospital. As an observational multicentric study using pre-existing data, patients and their parents were individually informed in writing to ensure their non opposition. Formal IRB was not required according to the legislation in our country.
: Not applicable.
: P. Quartier received consultancy or speaking fees from AbbVie, Bristol-Myers Squibb, Chugai-Roche, Lilly, Novartis, Novimmune, and Swedish Orphan Biovitrum; and participated in a data safety monitoring board for Sanofi.C. Pajot received consultancy or speaking fees from AbbVie.